Testing MAR002 for Acromegaly (a Pituitary Tumor Condition)
Part of Bones, joints & muscles, Brain & nervous system, Hormones & metabolism clinical trials.
This study tests a new drug called MAR002 to treat acromegaly, a hormone disorder caused by a pituitary tumor that makes too much growth hormone. The drug is designed to help lower hormone levels and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have confirmed acromegaly with a pituitary tumor shown on imaging or biopsy and elevated growth hormone levels
- Your IGF-1 hormone level must be elevated (at least 1.3 times the upper normal limit) based on two blood tests a week apart
- You weigh at least 50 kg (about 110 pounds)
- If you take acromegaly medications, you must be willing to stop them during the study per the protocol
- If you have low thyroid or adrenal hormone levels, they must be properly treated and stable
- You cannot have had pituitary surgery in the past 6 months or prior radiation to the pituitary
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new investigational drug called MAR002 in healthy men. The goal is to see how safe the drug is and how the body handles it before moving to larger studies.
This study follows people with acromegaly to better understand how treatments are used in real life and how well they work over time. It may help improve future treatment choices by comparing outcomes across different care patterns.
This trial tests a new medication, Debio 4126, for people with acromegaly who are already being treated with octreotide or lanreotide. The goal is to see if it can help control hormone levels and is safe to use.
This trial tests if switching from a standard somatostatin analog to pasireotide can better control acromegaly in patients whose growth hormone and IGF-1 levels remain high. It aims to offer a more effective treatment option for those not responding well enough to initial therapy.
This study tests a simple recognition tool to help tell whether someone has acromegaly or not. It may be useful for faster, easier identification of the condition.
This study looks at how treatments for acromegaly affect how you function and move, especially in your hands, feet, and overall body structure. You may be asked to do assessments to understand changes over time and whether certain groups respond differently.
Hear when a new Acromegaly trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.